Core Insights - The company reported a revenue of 1.593 billion yuan for the first three quarters, representing a year-on-year increase of 7.71% [1] - The net loss attributable to shareholders was 24.0489 million yuan, with a basic loss per share of 0.0173 yuan [1] Financial Performance - Revenue: 1.593 billion yuan, up 7.71% year-on-year [1] - Net Loss: 24.0489 million yuan [1] - Basic Loss per Share: 0.0173 yuan [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 CSPC PHARMACEUTICAL GROUP LIMITED 石藥集團有限公司 （股份代號：1093） （於香港註冊成立之有限公司） 石 藥 創 新 製 藥 股 份 有 限 公 司 截 至2025年9月30日 止 九 個 月 之 未 經 審 核 財 務 資 料 按 深 圳 證 券 交 易 所 之 相 關 規 定，石 藥 集 團 有 限 公 司（「本 公 司」）附 屬 公 司 石 藥 創 新 製 藥 股 份 有 限 公 司（「石 藥 創 新」，其 股 份 於 深 圳 證 券 交 易 所 創 業 板 上 市（股 票 代 碼：300765））， 已 於2025年10月27日 發 佈 其 截 至2025年9月30日 止 九 ...

Core Viewpoint - The biotechnology and innovative pharmaceutical industry in China has experienced volatility due to previous overvaluation, uncertainty in national medical insurance drug pricing, delays in business expansion expectations, and year-end fund sell-offs [1] Group 1: Market Conditions - Market liquidity remains robust, making valuations of quality companies increasingly attractive [1] - Ongoing business expansion activities are noted, with the potential for large transactions still possible [1] - Further downside price risk appears limited, indicating a healthy consolidation phase [1] Group 2: Company-Specific Insights - For CSPC Pharmaceutical Group (01093), delays in business expansion execution have weakened investor confidence, creating more attractive buying opportunities [1] - Assuming business expansion resumes as expected, the price-to-earnings (P/E) valuation remains very attractive for CSPC [1] - The third-quarter performance may serve as a recent catalyst for CSPC [1] Group 3: Future Outlook - The likelihood of significant progress on large business expansion transactions is high for next year [1] - For China National Pharmaceutical Group (01099), improvements in accounts receivable days and the initiation of the "14th Five-Year Plan" will support the recovery of profit momentum [1] - Current stock price levels offer an appealing dividend yield and low P/E ratio, with significant upside potential as operational efficiency continues to improve [1]

Core Viewpoint - The biotechnology and innovative pharmaceutical industry in China has experienced volatility due to high valuations from previous increases, uncertainty in national medical insurance drug pricing, delays in business expansion expectations, and year-end fund sell-offs [1] Industry Summary - The market liquidity remains robust, making valuations of quality companies increasingly attractive [1] - Business expansion activities are ongoing, with the potential for large transactions still possible, and further downside price risks appear limited [1] - The rising proportion of innovative drugs and accelerated profit growth indicate that the current pullback is a healthy consolidation, providing attractive opportunities for deployment in the coming year [1] Company Summary - For CSPC Pharmaceutical Group (01093), delays in business expansion execution have weakened investor confidence, creating a more attractive buying opportunity [1] - Assuming business expansion resumes as expected, the price-to-earnings ratio remains very attractive [1] - The possibility of completing several smaller business expansion transactions before year-end is still likely, with Q3 performance potentially serving as a recent catalyst [1] - For Sinopharm Group (01099), improvements in accounts receivable days and the initiation of the "14th Five-Year Plan" will support the recovery of profit momentum [1] - Current stock price levels offer an appealing dividend yield and a low price-to-earnings ratio, with significant upside potential as operational efficiency continues to improve [1]

Market Overview - The market sentiment was boosted by progress in US-China trade talks, leading to a rise in Hong Kong's three major indices, with the Hang Seng Index increasing by 1.05% to 26,433.7 points and a total trading volume of HKD 267.08 billion [1] - According to China Merchants Securities, the recent adjustments in the Hong Kong market were seen as excessive, and the easing of the trade war along with incremental policy releases are expected to support a rebound in the market [1] Blue-Chip Stocks Performance - WuXi AppTec (02359) saw a significant increase of 4.07%, closing at HKD 115, contributing 3.09 points to the Hang Seng Index, with a revenue of RMB 32.86 billion for the first three quarters of 2025, up 18.6% year-on-year, and a net profit of RMB 12.076 billion, up 84.84% [2] - Other notable blue-chip stocks included Baidu Group-SW (09888) rising by 6.2% to HKD 125.1, and Semiconductor Manufacturing International Corporation (00981) increasing by 3.5% to HKD 82.8 [2] Sector Highlights - Large technology stocks experienced gains, with Baidu up over 6%, Alibaba up over 3%, and Tencent up 2.9%, driven by preliminary agreements on tariffs between the US and China [3] - The cryptocurrency market surged, with Bitcoin surpassing USD 115,000, and related stocks performing well, such as New Fire Technology Holdings (01611) up 17.81% [3] - Semiconductor stocks also saw a rise, with InnoCare Pharma (02577) increasing by 12.73% and Huahong Semiconductor (01347) up 4.98% [4] Nuclear Power Sector - The nuclear power sector showed strong performance, with Harbin Electric (01133) rising by 11.44% and China National Nuclear Power (02302) up 10.53%, supported by government initiatives for future industry development [6] Copper Industry Insights - The copper sector experienced a general increase, with China Daye Non-Ferrous Metals (00661) rising by 11.11%, driven by improved downstream purchasing and concerns over future supply tightness [7] Notable Stock Movements - Huaxin Cement (06655) rose by 10.23% after reporting a revenue of RMB 25.033 billion for the first three quarters of 2025, a 1.27% increase year-on-year [8] - Baidu Group-SW (09888) was highlighted for its transition towards AI, with a valuation shift expected as it integrates AI technology into its core business [9] - Guangqi Group (02238) reported a revenue decline of 10.49% year-on-year, resulting in a net loss of approximately RMB 4.312 billion for the first three quarters of 2025 [11]

Investment Rating - The report maintains an "Overweight" rating for several pharmaceutical companies including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, and Jiangsu Nhwa Pharmaceutical, with related targets such as CSPC Innovation Pharmaceutical [6][28]. Core Insights - The innovative drug sector is experiencing high prosperity, and the report continues to recommend innovative drugs and their industry chain. It highlights the recent global strategic collaboration between Innovent Biologics and Takeda, which is expected to catalyze the innovative drug market [6][29]. - The report notes that the A-Shares pharmaceutical sector underperformed the market in the fourth week of October 2025, with the SW Pharmaceutical and Biological index rising only 0.6% compared to a 2.9% increase in the SHCOMP [8][30]. - In the same period, the Hong Kong pharmaceutical sector also underperformed, while the U.S. pharmaceutical sector performed in line with the market [31][19]. Summary by Sections Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the ongoing recommendation of innovative drugs and the industry chain, maintaining "Overweight" ratings for various companies including Heng Rui Medicine, Hansoh Pharmaceutical, 3SBio, and Nhwa Pharmaceutical. It also recommends Biopharma/Biotech companies with innovative pipelines and increasing performance, maintaining "Overweight" ratings for Innovent Biologics, Xiamen Amoytop Biotech, and others [6][28]. Performance of A-Shares Pharmaceutical Sector - In the fourth week of October 2025, the A-Shares pharmaceutical sector's performance was weaker than the overall market, with a 0.6% increase compared to the SHCOMP's 2.9% rise. The medical service, pharmaceutical commerce, and medical equipment sub-sectors showed relatively better performance [8][30]. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector underperformed the market with a decline of 0.8%, while the U.S. pharmaceutical sector matched the market performance with a 1.9% increase. Notable stock movements included significant gains for companies like WuXi AppTec and declines for Alphamab Oncology in Hong Kong [31][19].

Macro Commentary - The US September CPI year-on-year growth rate continues to rise slightly but is below market expectations, with core CPI showing a month-on-month slowdown [2] - The Federal Reserve is expected to focus more on employment risks, with a potential interest rate cut in October or December, targeting a year-end federal funds rate of 3.75%-4% [2] - The Chinese stock market saw gains, with sectors like materials, consumer discretionary, and information technology leading, while utilities, consumer staples, and real estate lagged [4] Industry Commentary - The MSCI China Healthcare Index has risen 58.6% since the beginning of 2025, outperforming the MSCI China Index by 24.2%, indicating a recovery in the pharmaceutical sector [5] - The CXO industry is expected to see performance recovery in the second half of 2025 due to a resurgence in demand for innovative drug development and a rebound in capital market financing [5] - The report highlights the importance of clinical progress for authorized innovative drug pipelines overseas as a catalyst for stock price increases [7] Company Commentary - Great Wall Motors reported a slight decline in gross margin in Q3 2025, with a 3.6% increase in average selling price, but net profit fell 50% to 2.3 billion yuan due to delays in tax refunds [9] - The company maintains a sales forecast of 1.35 million units for 2025, with expectations for Q4 sales to reach 430,000 units, reflecting an 11% year-on-year growth [9] - Xiaomi is expected to report a strong Q3 2025 performance, with a projected 60% year-on-year increase in adjusted net profit, driven by robust electric vehicle sales [14] - Weibo anticipates a 5% decline in total revenue for Q3 2025, primarily due to weaker advertising demand from certain industries [15]

Core Viewpoint - The Chinese biotechnology and innovative pharmaceutical industry has experienced volatility due to previous overvaluation, uncertainty in national medical insurance drug pricing, delays in business expansion expectations, and year-end fund sell-offs [1] Industry Summary - Market liquidity remains robust, making valuations of quality companies increasingly attractive [1] - Business expansion activities are ongoing, with the potential for large transactions still present, and further price downside risks appear limited [1] - The rising proportion of innovative drugs and accelerated profit growth indicate that the current pullback is a healthy consolidation, providing attractive opportunities for deployment in the coming year [1] Company Summary - For CSPC Pharmaceutical Group, delays in executing business expansion have weakened investor confidence, creating more attractive buying opportunities; assuming business expansion resumes as expected, its price-to-earnings ratio remains very appealing [1] - The company is expected to complete several smaller business expansion transactions before year-end, with third-quarter performance potentially serving as a recent catalyst [1] - For Sinopharm Group, improvements in accounts receivable days and the initiation of the 14th Five-Year Plan will support the recovery of profit momentum; the current stock price offers an attractive dividend yield and a low price-to-earnings ratio, indicating significant upside potential as operational efficiency continues to improve [1]

Market Overview - The Hang Seng Index and the Hang Seng China Enterprises Index closed at 26,160 points and 9,364 points respectively, rising 3.6% and 3.9% over the week[1] - Total trading volume for the week was HKD 12,032 billion, down 33.0% from HKD 17,951 billion the previous week, indicating a cautious investor sentiment[1] - Sector performance showed Energy, Consumer Discretionary, Financials, and Information Technology rising by 5.5%, 5.7%, 3.3%, and 4.6% respectively, while Healthcare and Utilities fell by 0.9% and 0.01%[1] Stock Performance - Semiconductor Manufacturing International Corporation (981 HK) and Techtronic Industries (669 HK) led the gains, rising 15.8% and 10.7% respectively[1] - Pop Mart International (9992 HK) and Shanghai Pharmaceuticals (1093 HK) were the biggest losers, declining 16.3% and 9.9% respectively[1] Economic Indicators - The U.S. Consumer Price Index (CPI) for September increased by 3.0% year-on-year, slightly above August's 2.9% but below the market forecast of 3.1%[3] Trade Relations - Recent U.S.-China trade talks in Kuala Lumpur resulted in preliminary agreements on several key issues, including maritime logistics and tariff extensions, which may positively impact market sentiment[2] Industry Trends - The recent Fourth Plenary Session emphasized high-level technological self-reliance and new quality productivity, suggesting a continued focus on high-end manufacturing as a key investment theme in Hong Kong stocks[4] - The electric equipment sector showed strong performance, with companies like Dongfang Electric (1072 HK) and Harbin Electric (1133 HK) rising by 5.3% and 4.8% respectively[4]

Group 1 - The first batch of "doubling funds" has revealed heavy positions in core segments of the AI industry chain, with many actively managed equity funds achieving net value doubling this year due to early investments in AI-related sectors [1] - Traditional ETF products are facing stagnation, leading to a surge in differentiated products that provide more precise asset allocation tools, helping public funds break through growth bottlenecks in a crowded market [1] - The performance of companies listed on the Beijing Stock Exchange has shown steady growth, with many achieving both revenue and net profit increases, attracting more institutional investor attention [2] Group 2 - The domestic commercial insurance market for new energy vehicles has surpassed 100 billion yuan in premium income, growing by 36.6% year-on-year, significantly outpacing the overall car insurance market [3] - The eleventh batch of national drug procurement has begun, involving over 400 companies and 55 products, with new rules aimed at improving quality control and market competition [4] - Merge Labs, a brain-computer interface company co-founded by Sam Altman, is expected to adopt a non-invasive method combining gene therapy and ultrasound [4] Group 3 - 澜起科技 has successfully mass-produced the DDR5 fourth-generation RCD chip, which is a core component for high-performance server and data center memory systems [6] - 八一钢铁 plans to invest up to 35 million yuan in a new 3500mm pre-straightening machine project to enhance production quality [7] - 凯龙高科 intends to sell up to 122.33 million shares of repurchased stock to supplement its working capital [8] Group 4 - 北鼎股份 reported significant growth in its domestic self-owned brand categories, with Sam's Club becoming a key channel for sales [9] - 贵州百灵's net profit dropped by 35% in the first three quarters, with its controlling shareholder facing a significant lawsuit [10] - 德龙汇能 is planning a change in control, leading to a temporary suspension of its stock [11] - 中元股份 is also suspending trading due to the announcement of a significant matter [12] Group 5 - The three major U.S. stock indices rose last Friday, with the S&P 500 and Nasdaq reaching new highs, driven by a slowdown in core CPI growth and expectations of interest rate cuts [13] - Gold prices initially fell before rising 2.44% after the CPI data release, while oil prices experienced a slight decline [14]